Institute of Pathology, Technische Universität München, München, Germany.
Histopathology. 2013 Aug;63(2):234-41. doi: 10.1111/his.12150. Epub 2013 Jun 6.
Follicular thyroid carcinoma (FTC) has been a diagnostic challenge for decades. The PAX8-PPARγ rearrangement has been detected in FTC and classic papillary thyroid carcinomas (PTCs). The aims of this study were to assess the presence of PAX8-PPARγ by using tissue microarrays in a large cohort of different thyroid neoplasms, and to assess its diagnostic and prognostic implications.
Fluorescence in-situ hybridization (FISH) analysis for PAX8-PPARγ was performed on 226 thyroid tumours, comprising FTCs (n = 59), PTCs (n = 126), poorly differentiated thyroid carcinomas (PDs; n = 34), follicular thyroid adenomas (FTAs; n = 5), and follicular tumours of unknown malignant potential (FTUMPs; n = 2). PAX8-PPARγ was detected in 12% of FTCs, 1% of PTCs, 7% of PDs, and in both cases of FTUMP. There was no correlation between the extent of capsular or vascular invasion and PAX8-PPARγ, or between lymph node or haematogenous metastasis and PAX8-PPARγ. Overall survival (OS), tumour-specific survival (TSS) and relapse-free-survival (RFS) were not influenced by PAX8-PPARγ.
In this study, we demonstrate for the first time the presence of PAX8-PPARγ in PDs and FTUMPs, whereas in FTCs and PTCs the prevalence of PAX8-PPARγ is lower than previously reported. PAX8-PPARγ did not correlate with invasiveness or affect prognosis in any tumour type.
滤泡状甲状腺癌(FTC)几十年来一直是诊断上的挑战。PAX8-PPARγ 重排已在 FTC 和经典型甲状腺乳头状癌(PTC)中被检测到。本研究的目的是在一个不同甲状腺肿瘤的大队列中使用组织微阵列评估 PAX8-PPARγ 的存在,并评估其诊断和预后意义。
对 226 个甲状腺肿瘤(包括 59 例 FTC、126 例 PTC、34 例低分化甲状腺癌(PD)、5 例滤泡状甲状腺腺瘤(FTA)和 2 例滤泡性肿瘤恶性潜能不明(FTUMP))进行了 PAX8-PPARγ 的荧光原位杂交(FISH)分析。在 12%的 FTC、1%的 PTC、7%的 PD 和 2 例 FTUMP 中检测到了 PAX8-PPARγ。PAX8-PPARγ 的范围与包膜或血管侵犯之间、与淋巴结或血液转移之间均无相关性。总体生存(OS)、肿瘤特异性生存(TSS)和无复发生存(RFS)不受 PAX8-PPARγ 的影响。
在这项研究中,我们首次证明了 PAX8-PPARγ 在 PD 和 FTUMP 中的存在,而在 FTC 和 PTC 中,PAX8-PPARγ 的患病率低于先前报道。PAX8-PPARγ 与侵袭性无关,也不影响任何肿瘤类型的预后。